Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
PR Newswire —
BOULDER, Colo., March 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on...